, Tracking Stock Market Picks
Enter Symbol:
Cardium Therapeutics Inc. (CRXM) [hlAlert]

down 96.02 %

Cardium Therapeutics Inc. (CXM) rated Buy with price target $1.50 by Dawson James

Posted on: Tuesday,  Apr 20, 2010  12:25 PM ET by Dawson James

Dawson James rated Buy Cardium Therapeutics Inc. (OTCBB: CRXM) on 04/20/2010, when the stock price was $9.80. Since
then, Cardium Therapeutics Inc. has lost 96.02% as of 08/27/2015's recent price of $0.39.
If you would have followed this Dawson James's recommendation on CRXM, you would have lost 96.02% of your investment in 1955 days.

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium?s lead product candidate, Generx (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina.

Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology with a staff of over 50 investment professionals ensures our clients stay ahead of the constant changes in the healthcare capital markets. From our widely-respected institutional research, investment banking and high net worth services to our personalized attention for individual accounts, we provide quality service for our clients. We take pride in the quality and depth of our professionals and encourage you to contact us so we can begin serving your financial needs today.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/20/2010 12:25 PM Buy
9.80 30.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy